research Re‐Innovation in Clinical Trial Designs Based on Precision Therapy
Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
Search
for
Sort by
Research
240-270 / 1000+ results research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research A Botanical Compound for the Treatment of Alopecia Areata and Chemotherapy-Induced Alopecia
The botanical treatment for hair loss shows promise, especially for children.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
research Development of Uniform Protocol for Alopecia Areata Clinical Trials
A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research Successful treatment of severe diffuse alopecia areata with abrocitinib
Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
Ritlecitinib shows promise in improving severe alopecia areata, with 27% of patients seeing success.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
research Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
Abrocitinib may help treat alopecia areata effectively with mild side effects.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study
research A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia
research 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program
research Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial
Topical treatment SM04554 safely promotes hair growth in male baldness.
research P146 A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata
Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.